HBMN:SWX
HBM Healthcare Investments AG
CHF 230,00
0,00%
(0,00) 1D
28 apr, 17:30:57 GMT+2 · CHF
search
Alle symbolen
1D
5D
1M
6M
YTD
1J
5J
MAX
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor HBMN genereren…
Openen
CHF 230,00
Hoog
CHF 231,50
Laag
CHF 228,50
Beursw.
1,55 mld.
Gem. vol.
6,52K
Volume
3,11K
Dividend
3,26%
Kwartaaldividend
CHF 1,87
Ex-dividenddatum
2 jul 2025
Koers/winst-verhouding
6,40
52 wk hoog
CHF 245,50
52 wk laag
CHF 157,40
WPA
CHF 35,93
Uitstaande aandelen
6,74 mln.
Nieuwsartikelen
Van bronnen op internet
FXStreet
·
5 minuten geleden
S&P 500 Futures (ES) Elliott Wave outlook: Cycle from March 31 low Nearing end [Video]
Simply Wall Street
·
15 minuten geleden
Is It Time To Reassess Weibo (WB) After Its Prolonged Share Price Slide?
富途牛牛
·
20 minuten geleden
Dow Jones Top Company Headlines at 1 AM ET: Starbucks Says Its Sales Rebound Is Gaining Momentum | The ...
MarketBeat
·
1 uur geleden
Short Interest in Intuit Inc. (NASDAQ:INTU) Expands By 36.7%
Profiel
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Over HBM Healthcare Investments AG
CEO-
Medewerkers-
Opgericht12 jul 2001
HoofdkantoorZug, Zug, Zwitserland
Sector-
Websitehbmhealthcare.com
AI-content kan fouten bevatten. Meer informatie